Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Media

AIM Rule 26

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

SP Angel Note.pdf

Analyst coverage: SP Angel has released a new research note on N4 Pharma (AIM:N4P), reaffirming their Speculative Buy rating and setting a target price of 2.3p.

The note highlights N4’s proprietary delivery system, Nuvec®, and its growing potential in siRNA and DNA applications. With positive recent data in siRNA delivery, a broadened partner outreach strategy, and a strong balance sheet post-Placing, the company is entering a critical commercialisation phase.

SP Angel sees a clear path to value creation, particularly if partnering discussions progress or additional data further validates Nuvec®'s capabilities.

Read the full analyst note below and don’t forget to submit your questions for the N4 team.

SP Angel - Advancing Nuvec® to commercialisation